Alexandra Bruel[1], David Kavanagh[2], Marina Noris[3], Yahsou Delmas[4], Edwin K.S.Wong[2], Elena Bresin[3], François Provôt[5], Vicky Brocklebank[2], Caterina Mele[3], Giuseppe Remuzzi[3,6], Chantal Loirat[7], Véronique Frémeaux-Bacchi[8*] and Fadi Fakhouri[1*]

[1]Department of Nephrology and Immunology and Institut Transplantation, Urologie et Néphrologie, Centre Hospitalier Universitaire (CHU) de Nantes, Nantes, France.

[2]National Renal Complement Therapeutics Centre, Institute of Genetic Medicine, Newcastle University, United Kingdom.

[3]Istituto di Ricovero e Cura a Carattere Scientifico, Istituto di Ricerche Farmacologiche "Mario Negri," Clinical Research Center for Rare Diseases "Aldo e Cele Daccò," Ranica, Italy.

[4]Department of Nephrology, CHU de Bordeaux, Bordeaux, France.

[5]Department of Nephrology, CHU de Lille, Lille, France.

[6] University of Milan, Milan, Italy.

[7]Assistance Publique-Hôpitaux de Paris, Department of Pediatric Nephrology, Hôpital Robert Debré, Université Paris Diderot, Sorbonne Paris Cité, Paris.

[8]Assistance Publique-Hôpitaux de Paris, Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche S1138, Complément et Maladies, Centre de Recherche des Cordeliers, Paris, Department of Biological Immunology, Hôpital Européen Georges Pompidou, Paris.

*Contributed equally to the study.

Number of cases	**Total = 87**
United Kingdom	24
France	33
Italy	30
Year of diagnosis	
1983-1989	4
1990-1999	18
2000-2009	46
2010-2013	12
NA	7

Supplemental table 1: Distribution of 87 cases of pregnancy-associated hemolytic uremic syndrome (P-HUS) according to the country of the referral center and the year of diagnosis.

	CFH n=26	CFI n=8	MCP n=3	THBD N=1	C3 n=3	Combined n=8
At onset						
Age (years)	26.3 ± 4.9	28.1 ± 6.7	31.5 ± 14.8	30	31.3 ± 8.3	29.8 ± 5.7
Occurrence during pregnancy	4 (19%)	5 (63%)	1 (50%)	0	0 (0%)	0 (0%)
Need for dialysis	18 (78%)	6 (86%)	1(50%)	1	4 (100%)	7 (88%)
Neurological involvement	4 (19%)	0 (0%)	1 (50%)	0	0 (0%)	1 (13%)
Outcome						
HUS relapse	6 (38%)	3 (38%)	1 (50%)	0	1 (50%)	3 (50%)
CKD	6 (25%)	2 (25%)	0	0	1 (33%)	0 (0%)
ESRD	13 (54%)	6 (75%)	2 (100%)	1	2 (67%)	5 (71%)

Supplemental table 2: Characteristics at presentation and outcome of pregnancy-associated hemolytic uremic syndrome (HUS) according to the type of complement genes variants detected.

Abbreviations: CFH, complement factor H. CFI, complement factor I. MCP, membrane cofactor protein. FB, factor B. CKD, chronic kidney disease. ESRD, end-stage renal disease.